This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Awards highlight Avantor's commitment to the Biopharma industry
The company offers customized formulations tailored to align with each brand’s identity and consumer needs
L-HPC was independently developed by Shin-Etsu Chemical as a disintegrant for tablets
Over the last two years, Lupin has showcased exceptional improvement in its EcoVadis scoring
Subscribe To Our Newsletter & Stay Updated
